Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure.

Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a dysregulated immune disorder in children, associated with Epstein–Barr virus (EBV) infection or malignancies. In severe forms, HLH presents with signs and symptoms of hyperinflammation that progress to life-threatening multiorgan failure. I...

Descripción completa

Detalles Bibliográficos
Publicado en:Pediatric Nephrology Vol. 38; no. 3; pp. 927 - 932
Autores principales: Goldstein, Stuart L., Yessayan, Lenar T., Krallman, Kelli A., Collins, Michaela, Benoit, Stefanie, Westover, Angela, Humes, H. David
Formato: case study pictorial research tables/charts Journal Article
Publicado: Springer Nature Mar2023
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=161327149&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 161327149
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        0931041X
        EF1
      jtl: Pediatric Nephrology
      issn: 0931041X
      maglogo: N
    pubinfo:
      dt: Mar2023
      vid: 38
      iid: 3
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        161327149
        161327149
        161327149
        10.1007/s00467-022-05692-1
        161327149
      ppf: 927
      ppct: 5
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure.
      aug:
        au:
          Goldstein, Stuart L.
          Yessayan, Lenar T.
          Krallman, Kelli A.
          Collins, Michaela
          Benoit, Stefanie
          Westover, Angela
          Humes, H. David
        affil: Center for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 7022, 45229, Cincinnati, Ohio, USA
      sug:
        subj:
          Hemophagocytic Lymphohistiocytosis Diagnosis
          Hemophagocytic Lymphohistiocytosis Therapy
          Epstein-Barr Virus Infections Diagnosis
          Epstein-Barr Virus Infections Therapy
          Lymphoma, T-Cell Diagnosis
          Continuous Renal Replacement Therapy Methods
          Hematopoietic Stem Cell Transplantation Methods
          Treatment Outcomes
          Infant
          Multiple Organ Dysfunction Syndrome
          Biological Markers Blood
          Immune System Physiology
          Extracorporeal Circulation
          Infant: 1-23 months
      ab: Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a dysregulated immune disorder in children, associated with Epstein–Barr virus (EBV) infection or malignancies. In severe forms, HLH presents with signs and symptoms of hyperinflammation that progress to life-threatening multiorgan failure. Intervention with an extracorporeal immunomodulatory treatment utilizing a selective cytopheretic device (SCD) could be beneficial. The SCD with regional citrate anticoagulation selectively binds the most highly activated circulating neutrophils and monocytes and deactivates them before release to the systemic circulation. Multiple clinical studies, including a multicenter study in children, demonstrate SCD therapy attenuates hyperinflammation, resolves ongoing tissue injury and allows progression to functional organ recovery. We report the first case of SCD therapy in a patient with HLH and multi-organ failure. Case diagnosis/treatment: A previously healthy 22-month-old toddler presented with fever, abdominal distension, organomegaly, pancytopenia, and signs of hyperinflammation. EBV PCR returned at > 25 million copies. The clinical and laboratory pictures were consistent with systemic EBV-positive T-cell lymphoma with symptoms secondary to HLH. The patient met inclusion criteria for an ongoing study of integration of the SCD with a continuous kidney replacement therapy (CKRT) as part of standard of care. The patient received CKRT-SCD for 4 days with normalization of serum markers of sepsis and inflammation. The patient underwent hematopoietic stem cell transplantation 52 days after presentation and has engrafted with normal kidney function 8 months later. Conclusions: SCD treatment resulted in improvement of poor tissue perfusion reflected by rapid decline in serum lactate levels, lessened systemic capillary leak with discontinuation of vasoactive agents, and repair and recovery of lung and kidney function with extubation and removal of hemodialysis support.
      pubtype: Academic Journal
      doctype:
        case study
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N